Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership
CONCLUSION: All relevant stakeholders in the CRC PSP worked together to identify and prioritize the top 10 evidence uncertainties. The results give researchers and funding bodies the opportunity to address the most patient-relevant research projects. It is the first detailed description of a PSP in Germany, and the first PSP on CRC care worldwide.PMID:35579718 | DOI:10.1007/s00432-022-04042-w (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 17, 2022 Category: Cancer & Oncology Authors: Rosa Klotz Magdalena Holze Colette D örr-Harim Erich Grohmann Barbara Nied Burkhard Lebert Susanne Weg-Remers Claudia Lutz Karin Mei ßler Patrick Schloss Charlotte Ullrich Susanne Frankenhauser Heidi Lutter Diedrich B ühler Azaz Ahmed Toto Gronlund And Source Type: research

HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14. doi: 10.1200/EDBK_351354.ABSTRACTHuman epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti-EGFR therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of HER2 in metastatic ...
Source: Clinical Colorectal Cancer - May 17, 2022 Category: Cancer & Oncology Authors: Selma Ahcene Djaballah Francesca Daniel Anna Milani Gianmarco Ricagno Sara Lonardi Source Type: research

Adenoma and Sessile Serrated Lesion Detection Rates at Screening Colonoscopy for Ages 45-49 Years vs. Older Ages Since the Introduction of New Colorectal Cancer Screening Guidelines
CONCLUSIONS: In our healthcare system, a lower CRC screening initiation age has modestly affected colonoscopy volume by age without compromising screening yield. Lesion detection rates, including for advanced adenomas, in average-risk 45-49 year-olds approximate those in 50-54 year-olds at first-time screening, and 60-64 year-olds at re-screening. National monitoring is needed to assess fully the impact of lowering the CRC screening initiation age.PMID:35580769 | DOI:10.1016/j.cgh.2022.04.037 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 17, 2022 Category: Cancer & Oncology Authors: Uri Ladabaum John Shepard Ajitha Mannalithara Source Type: research

Potentials of long non-coding RNAs as biomarkers of colorectal cancer
Clin Transl Oncol. 2022 May 17. doi: 10.1007/s12094-022-02834-7. Online ahead of print.ABSTRACTColorectal cancer (CRC) is the third most common malignant tumor worldwide and the fourth major cause of cancer-related death, with high morbidity and increased mortality year by year. Although significant progress has been made in the therapy strategies for CRC, the great difficulty in early diagnosis, feeble susceptibility to radiotherapy and chemotherapy, and high recurrence rates have reduced therapeutic efficacy resulting in poor prognosis. Therefore, it is urgent to understand the pathogenesis of CRC and unravel novel bioma...
Source: Clinical Colorectal Cancer - May 17, 2022 Category: Cancer & Oncology Authors: Yan Lv Yanhua Wang Zhikai Zhang Jiarui Bao Huahua Su Source Type: research

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
J Clin Oncol. 2022 May 16:JCO2200687. doi: 10.1200/JCO.22.00687. Online ahead of print.ABSTRACTPURPOSE: To provide guidance on exercise, diet, and weight management during active cancer treatment in adults.METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials evaluating the impact of aerobic and resistance exercise, specific diets and foods, and intentional weight loss and avoidance of weight gain in adults during cancer treatment, on quality of life, treatment toxicity, and cancer control. PubMed and the Cochrane Library were searched from January 2000 to May 2021. A...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Jennifer A Ligibel Kari Bohlke Anne M May Steven K Clinton Wendy Demark-Wahnefried Susan C Gilchrist Melinda L Irwin Michele Late Sami Mansfield Timothy F Marshall Jeffrey A Meyerhardt Cynthia A Thomson William A Wood Catherine M Alfano Source Type: research

Immunotherapy for Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00010-7. doi: 10.1016/j.hoc.2022.02.010. Online ahead of print.ABSTRACTColorectal cancer is a common malignancy that is frequently able to evade immune defenses. Although this may contribute to promoting and propagating cancer growth, recent advances suggest that for some tumors, particularly those with high levels of microsatellite instability and hypermutability from DNA mismatch repair defects, immunotherapy is effective to control tumor progression. Unfortunately, the overwhelming majority of patients have poor antitumoral immune cell penetration and fewer molecula...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Reetu Mukherji Benjamin A Weinberg Katrina S Pedersen Source Type: research

Hereditary Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00002-8. doi: 10.1016/j.hoc.2022.02.002. Online ahead of print.ABSTRACTAround 10% to 16% of colorectal cancer patients have a pathogenic variant in a cancer susceptibility gene. Some of these variants are in cancer genes that are associated with colorectal cancer while others are not. The hereditary colorectal cancer syndromes can be divided into two major categories, the nonpolyposis and the polyposis conditions. The nonpolyposis conditions can be divided into those that lead to colorectal tumors with defective mismatch repair and those that do not. The polyposis cond...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Heather Hampel Matthew F Kalady Rachel Pearlman Peter P Stanich Source Type: research

Management of Peritoneal Disease in Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00008-9. doi: 10.1016/j.hoc.2022.02.008. Online ahead of print.ABSTRACTColorectal cancer with peritoneal involvement is traditionally recognized as having a poor prognosis, with treatment initially limited to palliative systemic chemotherapy alone. The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy drastically altered the course of this disease entity and has demonstrated improvements in survival outcomes. Recent evidence has shown benefit of CRS but did not show benefit of HIPEC. Under the guidance of a multid...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Vanessa M Welten Nelya Melnitchouk Source Type: research

Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer
This article also reviews existing and emerging alterations in CRC and their respective therapeutic approaches.PMID:35577710 | DOI:10.1016/j.hoc.2022.02.009 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Midhun Malla Aparna R Parikh Source Type: research

Colorectal Cancer in Younger Adults
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00005-3. doi: 10.1016/j.hoc.2022.02.005. Online ahead of print.ABSTRACTContrary to decreasing incidence rate of colorectal cancer (CRC) in older adults, incidence rates have nearly doubled in younger adults (age <50 years) in the United States since the early 1990s. A similar increase has been observed across the globe. Despite overall population trends in aging, about 15% of CRCs will be diagnosed in younger adults by 2030. The mechanisms and factors contributing to early-onset CRC (EOCRC) remain puzzling, especially because most young adults diagnosed with CRC hav...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Pooja Dharwadkar Timothy A Zaki Caitlin C Murphy Source Type: research

The Gut Microbiome in Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00012-0. doi: 10.1016/j.hoc.2022.03.001. Online ahead of print.ABSTRACTThe gut microbiome is important in human health and disease. Recent studies have begun to elucidate its specific role in colorectal cancer. The gut microbiome seems to play an integral role in colorectal cancer initiation and progression, and oncologic drug metabolism and toxicity. This review examines the associations between the gut microbiome and colorectal cancer initiation, progression, and oncologic drug metabolism, highlighting proposed mechanisms and landmark publications in this field. It a...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Sorbarikor Piawah Evan J Walker Erin L Van Blarigan Chloe E Atreya Source Type: research

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
J Clin Oncol. 2022 May 16:JCO2200687. doi: 10.1200/JCO.22.00687. Online ahead of print.ABSTRACTPURPOSE: To provide guidance on exercise, diet, and weight management during active cancer treatment in adults.METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials evaluating the impact of aerobic and resistance exercise, specific diets and foods, and intentional weight loss and avoidance of weight gain in adults during cancer treatment, on quality of life, treatment toxicity, and cancer control. PubMed and the Cochrane Library were searched from January 2000 to May 2021. A...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Jennifer A Ligibel Kari Bohlke Anne M May Steven K Clinton Wendy Demark-Wahnefried Susan C Gilchrist Melinda L Irwin Michele Late Sami Mansfield Timothy F Marshall Jeffrey A Meyerhardt Cynthia A Thomson William A Wood Catherine M Alfano Source Type: research

Immunotherapy for Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00010-7. doi: 10.1016/j.hoc.2022.02.010. Online ahead of print.ABSTRACTColorectal cancer is a common malignancy that is frequently able to evade immune defenses. Although this may contribute to promoting and propagating cancer growth, recent advances suggest that for some tumors, particularly those with high levels of microsatellite instability and hypermutability from DNA mismatch repair defects, immunotherapy is effective to control tumor progression. Unfortunately, the overwhelming majority of patients have poor antitumoral immune cell penetration and fewer molecula...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Reetu Mukherji Benjamin A Weinberg Katrina S Pedersen Source Type: research

Hereditary Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00002-8. doi: 10.1016/j.hoc.2022.02.002. Online ahead of print.ABSTRACTAround 10% to 16% of colorectal cancer patients have a pathogenic variant in a cancer susceptibility gene. Some of these variants are in cancer genes that are associated with colorectal cancer while others are not. The hereditary colorectal cancer syndromes can be divided into two major categories, the nonpolyposis and the polyposis conditions. The nonpolyposis conditions can be divided into those that lead to colorectal tumors with defective mismatch repair and those that do not. The polyposis cond...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Heather Hampel Matthew F Kalady Rachel Pearlman Peter P Stanich Source Type: research

Management of Peritoneal Disease in Colorectal Cancer
Hematol Oncol Clin North Am. 2022 May 13:S0889-8588(22)00008-9. doi: 10.1016/j.hoc.2022.02.008. Online ahead of print.ABSTRACTColorectal cancer with peritoneal involvement is traditionally recognized as having a poor prognosis, with treatment initially limited to palliative systemic chemotherapy alone. The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy drastically altered the course of this disease entity and has demonstrated improvements in survival outcomes. Recent evidence has shown benefit of CRS but did not show benefit of HIPEC. Under the guidance of a multid...
Source: Clinical Colorectal Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Vanessa M Welten Nelya Melnitchouk Source Type: research